Anthem Biosciences Ltd Technical Momentum Shifts Amid Mixed Market Signals

Recent Price Movement and Market Context

Anthem Biosciences closed at ₹672.00 on 11 Mar 2026, up from the previous close of ₹660.00. The stock traded within a range of ₹665.90 to ₹686.70 during the day, showing intraday volatility but ending on a positive note. Over the past 52 weeks, the stock has seen a high of ₹873.25 and a low of ₹579.45, indicating a wide trading band and potential for both upside and downside movements.

Comparatively, the stock has outperformed the Sensex on a year-to-date basis, delivering a 3.22% return versus the Sensex’s decline of 8.23%. However, over shorter periods such as one week and one month, Anthem Biosciences has underperformed slightly, with returns of -2.13% and -0.69% respectively, against the Sensex’s -2.53% and -7.20%. This suggests some near-term weakness despite a relatively stronger performance over the longer term.

Technical Trend Shift: From Sideways to Mildly Bearish

The technical trend for Anthem Biosciences has shifted from a sideways consolidation phase to a mildly bearish trend. This change is significant as it signals a potential weakening in price momentum, which investors should monitor closely. The weekly Dow Theory assessment aligns with this view, indicating a mildly bearish outlook, while the monthly Dow Theory shows no clear trend, reflecting uncertainty over the longer term.

On the volume front, the On-Balance Volume (OBV) indicator is mildly bearish on both weekly and monthly charts, suggesting that selling pressure may be gradually increasing. This volume-based signal often precedes price declines, reinforcing the cautious stance.

MACD and RSI: Divergent Signals

The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. On the weekly timeframe, the MACD remains mildly bullish, indicating some underlying positive momentum. However, the monthly MACD does not provide a clear signal, reflecting a lack of strong directional conviction over the longer term.

Relative Strength Index (RSI) readings are neutral on both weekly and monthly charts, offering no definitive buy or sell signals. This lack of momentum in RSI suggests the stock is neither overbought nor oversold, which aligns with the broader theme of mixed technical signals.

Moving Averages and Bollinger Bands

While specific daily moving average values are not detailed, the overall technical summary indicates a cautious stance. The weekly Bollinger Bands are bullish, implying that price volatility is supporting upward momentum in the short term. Conversely, the monthly Bollinger Bands also show bullish tendencies, which may provide some support against the mildly bearish trend indicated by other metrics.

Mojo Score and Market Capitalisation Insights

Anthem Biosciences currently holds a Mojo Score of 40.0, which corresponds to a Sell rating, downgraded from a previous Hold on 09 Mar 2026. This downgrade reflects a deterioration in the stock’s technical and fundamental outlook as assessed by MarketsMOJO’s proprietary scoring system. The company’s market cap grade stands at 2, indicating a relatively small market capitalisation within its sector, which can contribute to higher volatility and risk.

The downgrade in Mojo Grade signals caution for investors, especially given the mixed technical signals and the mildly bearish trend shift. It is important to weigh these technical factors alongside the company’s fundamentals and sector dynamics before making investment decisions.

Long-Term Performance Relative to Sensex

Looking beyond the immediate technical indicators, Anthem Biosciences’ long-term returns present a more encouraging picture. While one-year, three-year, five-year, and ten-year stock returns are not available, the Sensex has delivered 5.52%, 32.25%, 52.51%, and 217.61% respectively over these periods. The stock’s positive year-to-date return of 3.22% against a Sensex decline suggests some resilience, but the absence of longer-term stock return data warrants a cautious approach.

Investor Takeaway: Navigating Mixed Signals

Investors in Anthem Biosciences should be mindful of the recent shift to a mildly bearish technical trend, despite some bullish signals from weekly MACD and Bollinger Bands. The neutral RSI and lack of clear monthly MACD direction add to the uncertainty. The downgrade in Mojo Grade to Sell further emphasises the need for prudence.

Given the stock’s volatility and mixed technical indicators, a cautious stance with close monitoring of price action and volume trends is advisable. Investors may consider waiting for clearer confirmation of trend direction or look for alternative opportunities within the Pharmaceuticals & Biotechnology sector.

Conclusion

Anthem Biosciences Ltd’s recent technical parameter changes highlight a nuanced shift in price momentum. While short-term indicators such as the weekly MACD and Bollinger Bands offer some bullish undertones, the overall trend has turned mildly bearish, supported by volume-based signals and a Mojo Grade downgrade. Investors should approach the stock with caution, balancing these technical insights against the company’s fundamentals and broader market conditions.

For those seeking more stable or promising opportunities within the Pharmaceuticals & Biotechnology sector, exploring alternative stocks with stronger technical and fundamental profiles may be prudent. Continuous monitoring of Anthem Biosciences’ price action and technical indicators will be essential to identify any reversal or further deterioration in trend.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today